Friedman H S, Kerby T, Fields S, Zilisch J E, Graden D, McLendon R E, Houghton P J, Arbuck S, Cokgor I, Friedman A H
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Cancer. 1999 Mar 1;85(5):1160-5.
Topotecan activity was evaluated for the treatment of malignant glioma.
Sixty-three patients with newly diagnosed (n = 25) or recurrent (n = 38) malignant glioma were treated with topotecan [AU: Please verify all dosages here and throughout text.]at a dose of 2.6 mg/m2 over a 72-hour period weekly. Recurrent tumors included glioblastoma multiforme (GBM) (n = 28) and anaplastic astrocytoma (AA) (n = 10). Newly diagnosed tumors included GBM (n = 14), AA (n = 8), and anaplastic oligodendroglioma (n = 3).
Partial responses were observed in 2 of 14 evaluable patients with newly diagnosed GBM, 1 of 8 patients with newly diagnosed AA, 3 of 10 patients with recurrent AA, and none of 28 patients with recurrent GBM. Four patients with recurrent AA and 7 patients with recurrent GBM demonstrated stable disease (range, 8-52 weeks; median, 21 weeks). Toxicity was limited to infrequent National Cancer Institute Common Toxicity Criteria Grade 3 myelosuppression.
These results suggest that topotecan has modest activity against malignant glioma and continued evaluation of its effectiveness may be warranted when alternative schedules or combination regimens are used.
评估了拓扑替康治疗恶性胶质瘤的活性。
63例新诊断（n = 25）或复发（n = 38）的恶性胶质瘤患者接受拓扑替康治疗，剂量为2.6mg/m²，每周持续72小时。复发性肿瘤包括多形性胶质母细胞瘤（GBM）（n = 28）和间变性星形细胞瘤（AA）（n = 10）。新诊断的肿瘤包括GBM（n = 14）、AA（n = 8）和间变性少突胶质细胞瘤（n = 3）。
14例可评估的新诊断GBM患者中有2例出现部分缓解，8例新诊断AA患者中有1例出现部分缓解，10例复发性AA患者中有3例出现部分缓解，28例复发性GBM患者中无1例出现部分缓解。4例复发性AA患者和7例复发性GBM患者病情稳定（范围8 - 52周；中位数21周）。毒性仅限于罕见的美国国立癌症研究所常见毒性标准3级骨髓抑制。
这些结果表明拓扑替康对恶性胶质瘤有一定活性，当采用其他给药方案或联合治疗方案时，可能有必要继续评估其有效性。
